miRNA-100 inhibits human bladder urothelial carcinogenesis by directly targeting mTOR

Molecular Cancer Therapeutics

Volumn 12, Issue 2, 2013, Pages 207-219

  Xu, Chuanliang ^a   Zeng, Qinsong ^a,b   Xu, Weidong ^a   Jiao, Li ^a   Chen, Yanqiong ^a   Zhang, Zhensheng ^a   Wu, Chengyao ^a   Jin, Taile ^a   Pan, Anyin ^a   Wei, Rongchao ^a   Yang, Bo ^a   Sun, Yinghao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 100; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; BLADDER CANCER; CANCER CELL CULTURE; CANCER TISSUE; CELL CYCLE ARREST; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC THERAPY; HUMANS; MICE; MICE, NUDE; MICRORNAS; TOR SERINE-THREONINE KINASES; TRANSFECTION; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874098541     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0273     Document Type: Article

References (49)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-36.
2. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158:62-7.
3. Pollard C, Smith SC, Theodorescu D. Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med 2010; 12:e10.
4. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10:704-14.
5. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10: 389-402.
6. Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 2011; 128:1758-69.
7. Uchida Y, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Kawahara K, et al. MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol Oncol. 2011 Mar 9. [Epub ahead of print].
8. Noguchi S, Mori T, Hoshino Y, Maruo K, Yamada N, Kitade Y, et al. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett 2011; 307:211-20.
9. Lu Q, Lu C, Zhou GP, Zhang W, Xiao H, Wang XR. MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. Urol Oncol 2010; 28:635-41.
10. Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H, et al. miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int J Oncol 2011; 39:13-21.
11. Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 2009; 69:8472-81.
12. Zheng YS, Zhang H, Zhang XJ, Feng DD, Luo XQ, Zeng CW, et al. MiR100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene 2012; 31:80-92.
13. Li BH, Zhou JS, Ye F, Cheng XD, Zhou CY, Lu WG, et al. Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein. Eur J Cancer 2011; 47:2166-74.
14. Dubeau L, Jones PA. Growth of normal and neoplastic urothelium and response to epidermal growth factor in a defined serum-free medium. Cancer Res 1987; 47:2107-12.
15. Dubeau L, Jones PA. A new in vivo model to study invasion and metastasis of human bladder carcinoma. Cancer Res 1987; 47: 6660-5.
16. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci 1998; 95:14863-68.
17. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:e179.
18. Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 2011; 15:2926-37.
19. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19:232-43.
20. Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, et al. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther 2000; 7:1575-80.
21. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25:25-29.
22. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003; 19:368-75.
23. Li C, Li H. Network-constrained regularization and variable selection for analysis of genomic data. Bioinformatics 2008; 24:1175-82.
24. Zhang JD, Wiemann S. KEGG graph: a graph approach to KEGG PATHWAY in R and bioconductor. Bioinformatics 2009; 25: 1470-71.
25. Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sørensen KD, et al. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 2010; 29:1073-84.
26. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 2010; 102:883-91.
27. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-484.
28. Sun Y, Fang R, LiC, Li L, Li F, Ye X, et al. Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem Biophys Res Commun 2010; 396:501-7.
29. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One 2011; 6:e18286.
30. Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman ES. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 2012; 72:908-16.
31. Li B, Shi XB, Nori D, Chao CK, Chen AM, Valicenti R, et al. Downregulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. Prostate 2011; 71:567-74
32. Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, MajjajS, et al. Global microRNAexpression profiling identifies miR-210 associated with tumor proliferation, invasion and poor clinical outcome n breast cancer. PLoS ONE 2011; 6:e20980.
33. Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T, Sartorelli V. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 2011; 32:1607-14.
34. Liu L, Yu X, Guo X, Tian Z, Su M, Long Y, et al. MiR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Report 2012; 5:753-60.
35. Feng B, Wang R, Chen LB. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 2012; 317:184-91
36. Nagaraja AK, Creighton CJ, YuZ, Zhu H, GunaratnePH, Reid JG, et al. A link between mir-100and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 2010; 24:447-63.
37. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Dall'Oglio MF, et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol 2011; 185: 1118-22.
38. Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, San̄udo A, et al. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancerto metastasis. Urol Oncol 2011; 29:265-9.
39. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-5.
40. Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 2010; 28:409-28.
41. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22.
42. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 2002; 9:99-100.
43. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, et al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 2010; 176: 3062-72.
44. Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 2009; 8:2339-47.
45. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). CurrOpin Oncol 2004; 16:564-75.
46. Zhou H, Huang S. mTOR signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Expr 2010; 20: 1-16.
47. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122-28.
48. Berven LA, Willard FS, Crouch MF. Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res 2004; 296:183-95.
49. Liu L, Chen L, Chung J, Huang S. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 2008; 27:4998-5010.